Tarsus Pharmaceuticals Future Growth
Future criteria checks 5/6
Tarsus Pharmaceuticals is forecast to grow earnings and revenue by 56.1% and 40.7% per annum respectively while EPS is expected to grow by 58.5% per annum.
Key information
56.1%
Earnings growth rate
58.5%
EPS growth rate
| Pharmaceuticals earnings growth | 22.9% |
| Revenue growth rate | 40.7% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 17 Apr 2024 |
Recent future growth updates
Recent updates
Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
Mar 08Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic
Mar 03
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 01Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Nov 12What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates
Aug 16Tarsus files for FDA approval of TP-03 to treat mite infestation in eyelids
Sep 07Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues
May 13A Look At The Fair Value Of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Dec 07Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 356 | 40 | N/A | N/A | 4 |
| 12/31/2025 | 207 | -78 | N/A | N/A | 6 |
| 12/31/2024 | 103 | -145 | N/A | N/A | 7 |
| 12/31/2023 | 17 | -136 | -123 | -117 | N/A |
| 9/30/2023 | 14 | -108 | -95 | -89 | N/A |
| 6/30/2023 | 13 | -91 | -77 | -75 | N/A |
| 3/31/2023 | 28 | -65 | -56 | -56 | N/A |
| 12/31/2022 | 26 | -62 | -50 | -49 | N/A |
| 9/30/2022 | 16 | -63 | -51 | -50 | N/A |
| 6/30/2022 | 17 | -56 | -25 | -25 | N/A |
| 3/31/2022 | 24 | -44 | 0 | 0 | N/A |
| 12/31/2021 | 57 | -14 | 3 | 4 | N/A |
| 9/30/2021 | 57 | -10 | 6 | 6 | N/A |
| 6/30/2021 | 55 | -5 | -8 | -8 | N/A |
| 3/31/2021 | 33 | -15 | -32 | -31 | N/A |
| 12/31/2020 | N/A | -27 | -22 | -21 | N/A |
| 9/30/2020 | N/A | -17 | -12 | -12 | N/A |
| 6/30/2020 | N/A | -7 | -6 | -6 | N/A |
| 3/31/2020 | N/A | -5 | -5 | -5 | N/A |
| 12/31/2019 | N/A | -5 | -4 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TARS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: TARS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TARS is expected to become profitable in the next 3 years.
Revenue vs Market: TARS's revenue (40.7% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: TARS's revenue (40.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TARS's Return on Equity is forecast to be high in 3 years time